Overview
Metastatic clear cell adenocarcinoma involving the ovary is a rare but challenging clinical scenario, often arising from primary tumors in other organs, particularly the stomach. This condition typically presents with complex clinical features and carries a guarded prognosis despite aggressive management strategies. The rarity of this metastasis necessitates a thorough understanding of its clinical presentation, diagnostic approaches, and treatment modalities to optimize patient outcomes. Evidence from various studies highlights the importance of considering patient demographics, tumor characteristics, and the timing of metastasis detection in guiding therapeutic decisions.
Clinical Presentation
Patients with metastatic clear cell adenocarcinoma to the ovary often present with nonspecific symptoms that can complicate early diagnosis. A notable case involved a 58-year-old woman with a history of high-grade serous carcinoma of the ovary, who relapsed seven years post-initial treatment with pericardial effusion and cardiac tamponade, indicative of advanced disease dissemination [PMID:30904894]. This presentation underscores the potential for late recurrence and the systemic nature of the disease.
Demographically, patients developing ovarian metastases tend to be predominantly non-Caucasian, suggesting potential ethnic disparities in disease behavior and outcomes [PMID:40446172]. Clinically, these metastases are frequently associated with peritoneal involvement, complicating both diagnosis and management. Histologically, the tumors often exhibit characteristics such as human epidermal growth factor receptor 2 (HER2) negativity, PD-L1 negativity, signet ring cell morphology, and a diffuse subtype, which can influence treatment strategies and prognosis [PMID:40446172]. Additionally, an elevated absolute lymphocyte count, particularly noted one month post-immunotherapy (IMT), has been associated with disease stabilization, contrasting with a lower lymphocyte count linked to disease progression [PMID:25951718]. This immunological marker may serve as a potential prognostic indicator in clinical practice.
Diagnosis
Diagnosing metastatic clear cell adenocarcinoma to the ovary requires a multifaceted approach, integrating clinical symptoms, imaging studies, and histopathological confirmation. Imaging modalities, including computed tomography (CT) scans and magnetic resonance imaging (MRI), play crucial roles in identifying metastatic lesions and assessing the extent of disease spread. In the aforementioned case, imaging studies and a two-dimensional echocardiogram confirmed massive pericardial effusion and cardiac tamponade, classified as New York Heart Association-IV, highlighting the severity and urgency of the clinical scenario [PMID:30904894].
Timing is critical in diagnosing these metastases. Studies indicate that patients with ovarian metastases from primary gastric adenocarcinoma often experience a shorter interval between the initial diagnosis of the primary tumor and the detection of ovarian metastases, suggesting early dissemination or delayed detection [PMID:40446172]. Histopathological examination remains definitive, confirming the clear cell morphology and ruling out other differential diagnoses. Given the rarity and complexity, multidisciplinary input from oncologists, radiologists, and pathologists is essential for accurate diagnosis and staging.
Management
The management of metastatic clear cell adenocarcinoma involving the ovary is multifaceted, often requiring a combination of surgical interventions, systemic therapies, and supportive care. In the case described, the patient underwent pericardiocentesis to relieve cardiac tamponade, followed by surgical intervention (pericardial window) and systemic chemotherapy with paclitaxel and carboplatin, complemented by maintenance therapy with olaparib, reflecting a comprehensive approach to address both immediate life-threatening issues and systemic disease [PMID:30904894].
Surgical options, such as palliative oophorectomy, have shown promise in improving survival outcomes. A retrospective analysis indicated that patients who underwent palliative oophorectomy had a significantly reduced hazard ratio for overall survival (0.5; 95% CI, 0.31 to 0.81) compared to those who did not, emphasizing the potential benefits of surgical intervention when feasible [PMID:40446172]. Immunotherapy (IMT), incorporating agents like picibanil (OK-432), interleukin-2, and interferon-α, has demonstrated efficacy in stabilizing disease in refractory or recurrent epithelial ovarian cancer, achieving a disease stabilization rate of 60% with manageable toxicity profiles [PMID:25951718]. However, conventional chemotherapy alone has shown limited efficacy, with only 24% of patients benefiting from this approach in a retrospective review of advanced or recurrent ovarian clear cell carcinoma [PMID:21463887]. In contrast, radiation therapy alone exhibited a higher treatment benefit rate (64%) compared to chemotherapy alone, suggesting its potential role in palliative management strategies [PMID:21463887].
Given the often aggressive nature of these metastases, clinicians must weigh the benefits of aggressive interventions against potential toxicities and patient tolerance. Tailoring treatment plans based on individual patient factors, including performance status and comorbidities, is crucial for optimizing outcomes.
Prognosis & Follow-up
Despite aggressive management strategies, the prognosis for patients with metastatic clear cell adenocarcinoma involving the ovary remains guarded. Aggressive interventions such as surgical resection and targeted chemotherapy can provide temporary stabilization but often fail to achieve long-term remission [PMID:30904894]. The median survival post-immunotherapy (IMT) for patients with refractory/recurrent epithelial ovarian cancer is approximately 12 months, highlighting the persistent challenges in managing this condition [PMID:25951718].
Vigilant follow-up is essential due to the high risk of recurrence and metastasis. Regular imaging studies, biomarker assessments, and clinical evaluations are necessary to monitor disease progression and detect early signs of relapse. The low benefit-to-failure ratio observed with conventional palliative chemotherapy underscores the need for exploring alternative and combination therapies, including targeted agents and immunotherapies, to enhance clinical outcomes [PMID:21463887]. Continuous research into novel therapeutic targets and personalized medicine approaches is critical for improving survival rates and quality of life in these patients.
Special Populations
Ethnic diversity significantly influences the clinical presentation and outcomes of metastatic clear cell adenocarcinoma involving the ovary. Studies emphasize that non-Caucasian patients are more frequently affected, with distinct survival benefits observed in multiethnic analyses [PMID:40446172]. These findings underscore the importance of considering ethnic characteristics in tailoring treatment strategies and predicting patient responses. Clinicians should be aware of potential disparities and tailor their approaches accordingly, possibly incorporating culturally sensitive care practices and targeted research to better understand and address these differences.
Key Recommendations
References
1 Dracham CB, Gupta S, Das CK, Elangovan A. Platinum sensitive carcinoma of ovary relapsed as pericardial effusion with cardiac tamponade. BMJ case reports 2019. link 2 Sewastjanow-Silva M, Xiao L, Abdelhakeem A, Pabon CM, Yamashita K, Yoshimura K et al.. Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025. link 3 Chen CY, Lai CH, Yang LY, Tang YH, Chou HH, Chang CJ et al.. Immunomodulatory therapy in refractory/recurrent ovarian cancer. Taiwanese journal of obstetrics & gynecology 2015. link 4 Al-Barrak J, Santos JL, Tinker A, Hoskins P, Gilks CB, Lau H et al.. Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecologic oncology 2011. link